Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
Show more...
CEO
Dr. Anirvan Ghosh Ph.D.
Karyawan
65
Negara
US
ISIN
US91381U1016
WKN
000A2JLUJ
Pencatatan
0 Comments
Bagikan pendapatmu
FAQ
Berapa harga saham Unity Biotechnology hari ini?▼
Harga saat ini dari 9U9.F adalah €0.37 EUR — turun sebesar -0.03% dalam 24 jam terakhir. Pantau kinerja harga saham Unity Biotechnology lebih dekat di grafik.
Apa simbol saham Unity Biotechnology?▼
Tergantung pada bursa, simbol saham dapat berbeda. Misalnya, di bursa , saham Unity Biotechnology diperdagangkan dengan simbol 9U9.F.
Berapa pendapatan Unity Biotechnology tahun lalu?▼
Pendapatan Unity Biotechnology tahun lalu berjumlah 225,191.2 EUR.
Berapa pendapatan bersih Unity Biotechnology tahun lalu?▼
Pendapatan bersih 9U9.F untuk tahun lalu adalah -30.87M EUR.
Berapa jumlah karyawan Unity Biotechnology?▼
Per April 06, 2026, perusahaan memiliki 65 karyawan.
Unity Biotechnology berada di sektor apa?▼
Unity Biotechnology beroperasi di sektor Healthcare.